Back to Recurring Families
KALSHI
MANIFOLD MARKETS
POLYMARKETKALSHIKALSHIKALSHIMANIFOLD MARKETSPOLYMARKETPOLYMARKETPOLYMARKETPOLYMARKET POLYMARKETPOLYMARKETPOLYMARKETPOLYMARKET
Regulatory Approvals & Licensing
Track recurring approval, licensing, and rule-change catalysts across regulatory markets.
RegulatoryScheduled
Next catalyst: Regulatory Approvals & Licensing · June 8, 2026 · June 8, 2026 at 3:00 AM
Compare-ready catalysts
0
These upcoming catalyst instances already carry approved cross-source linkage, so compare/alignment value remains available inside the recurring family.
Source footprint
3
The recurring family inherits the source footprint of its linked catalysts rather than inventing a separate data model.
Recurring cadence
Scheduled
Cadence stays descriptive and lightweight in v1 so recurring research surfaces remain easy to reason about.
How this family is grouped
This recurring layer stays conservative: a catalyst only joins this family when its title or linked-market family clearly matches these signals.
FDA approvalSEC changeLicense / reauthorization
Sources
The recurring family inherits the source footprint of its linked catalysts rather than inventing a separate data model.
KALSHIMANIFOLD MARKETSPOLYMARKETUpcoming catalyst instances
These upcoming catalyst instances reuse the current catalyst layer and preview the linked prediction markets directly on the page.
Jun 8, 2026, 3:00 AMFamily cluster
Regulatory Approvals & Licensing · June 8, 2026
2 linked markets·1 Sources
KALSHILinked markets
College Baseball: SEC Tournament Champion
KALSHIMarty Makary out as FDA commissioner?
KALSHIDec 31, 2026, 12:00 AMFamily cluster
Regulatory Approvals & Licensing · December 31, 2026
6 linked markets·2 Sources
MANIFOLD MARKETSPOLYMARKETLinked markets
FDA approves a psychedelic for medical use in 2026?
POLYMARKETSEC removes quarterly reporting requirement?
POLYMARKETWho will Trump announce as next FDA commissioner?
POLYMARKETRecent catalyst instances
Recent instances stay visible here when the current data still supports them, so the recurring family has context beyond the next catalyst.
Apr 30, 2026, 12:00 AMFamily cluster
Regulatory Approvals & Licensing · April 30, 2026
4 linked markets·1 Sources
POLYMARKETLinked markets
FDA approves AstraZeneca's Truqap (capivasertib)?
POLYMARKETFDA approves Axsome Therapeutics' AXS-05?
POLYMARKETFDA approves AstraZeneca's Camizestrant?
POLYMARKET